Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 688 for cancer

  • Results filtered:
  • Study status: Open/Status Unknown
Edit search filters
  1. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  2. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    Jacksonville, FL, Rochester, MN

  3. A Study of PF-08052666/​SGN-MesoC2 in Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study Of PARG Inhibitor ETX-19477 In Patients With Advanced Solid Malignancies (ERADIC8)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. INCB161734 for Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

    Scottsdale/Phoenix, AZ

  6. Study of RP-6306 Alone or in Combination With RP-3500 in Patients With Advanced Solid Tumors

    Jacksonville, FL, Rochester, MN

  7. A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  8. A First-in-Human Study of BG-C137, an Anti-FGFR2b Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

    Rochester, MN

  9. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    Jacksonville, FL, Rochester, MN

  10. A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors

    Scottsdale/Phoenix, AZ, Rochester, MN

.

Mayo Clinic Footer